Exabis Library
Welcome to the e-CCO Library!
P534: Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in Russia: results of the EXPLORE study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P534: Spontaneous intra-abdominal abscess in Crohn's disease: Efficacy of non-surgical management and prognostic factors
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P535 Effects of the Janus Kinase 1 (JAK1)-selective inhibitor filgotinib on circulating cytokines and whole-blood genes/pathways of patients with moderately to severely active Crohn’s disease (CD)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P535: Association of anti-Infliximab antibodies and HLADQA1*05 variant in ulcerative colitis : a retrospective single centre study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P535: Azathioprine vs. mesalamine for prevention of post-operative clinical relapse in Crohn’s disease patients with severe endoscopic recurrence: data on efficacy and safety from an IG-IBD multi-centre randomised double-blind double-dummy trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P535: COVID-19 vaccine-induced neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 are diminished in patients with inflammatory bowel disease on anti-TNF or JAK-inhibitor therapy
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P535: Optimising vedolizumab in treatment sequences for Crohn’s disease: Results from a simulation model using real-world evidence
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P535: Outcomes of endoscopic resections of large non-polypoid lesions inflammatory bowel disease: a single United Kingdom centre experience
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P535: The use of therapeutic drug monitoring for infliximab and adalimumab in inflammatory bowel disease: Practice patterns, understanding and interpretation
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P536 Early prediction of intravenous corticosteroid therapy failure in moderate–severe ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P536: Combination therapy of bone marrow mesenchymal stromal cells and azathioprine not affect the clinical course luminal Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P536: Comparison of outcomes of infliximab biosimilar CT-P13 with infliximab originator in patients with inflammatory bowel disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P536: Effectiveness, safety and persistence of treatment with ustekinumab in a cohort of patients with moderate-to-severe refractory Crohn's Disease.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P536: Is there any association between fat body mass and bone mineral density in patients with Inflammatory Bowel Disease?
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P536: Minimally invasive gasless technique for ileocolic resection using an existing McBurney incision
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P536: Thiopurine metabolite levels in pregnant IBD patients and infants following intrauterine thiopurine exposure
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P537 Real-world long-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA registry
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P537: Adalimumab: Relevance of drug trough levels and antibodies assessment in the prognosis of Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P537: Anemia in Crohn's Disease: Response to treatment and risk of recurrence
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P537: Is anti-TNF therapeutic drug monitoring of value in IBD patients in clinical remission?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM